Faron’s fundraising exceeded expectations
Panmure Gordon was sole UK bookrunner and corporate broker for Faron Pharmaceutical’s successful EUR14 million fundraising. The fundraising exceeded the company’s initial plans to raise EUR10m. The company will use the funds to invest in its immunotherapy and cancer treatments, and in a trial to explore a potential COVID-19 treatment.
This is the latest successful fundraising done by Panmure Gordon’s leading healthcare team, which recently raised £11.2 million for Diurnal in a transaction that also exceeded expectations.
Freddy Crossley, Head of Healthcare, said: “Faron’s fundraising exceeded expectations despite the challenging market conditions, which is testament to the quality of the company, its growth story and our commitment to help our clients raise funding for future growth.”